This site is intended for health professionals only

Published on 27 May 2015

Share this story:
Twitter
LinkedIn

STELARA® receives CHMP positive opinion for adolescents with moderate to severe psoriasis in Europe

Janssen-Cilag International NV (“Janssen”) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for the use of STELARA® (ustekinumab), for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

Janssen-Cilag International NV (“Janssen”) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for the use of STELARA® (ustekinumab), for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

The CHMP adopted the opinion based on a review of data from the CADMUS study, which is a Phase III, randomised, double-blind, placebo-controlled, multicentre trial designed to evaluate the safety and efficacy of STELARA in patients aged 12 to 17 years with moderate to severe plaque psoriasis. (1)

Today’s recommendation of STELARA for the treatment of paediatric psoriasis is an important step forward for adolescents living with this chronic, debilitating autoimmune disease”, said Newman Yeilding, MD, Vice President, Head of Immunology Development, Janssen Research & Development, LLC. “We look forward to the European Commission’s decision and the opportunity to bring STELARA to adolescent patients who could benefit from biologic therapy.

Based on the CHMP’s positive opinion, a final decision from the European Commission is expected during the third quarter of 2015. If approved, STELARA will become available for the treatment of adolescents from the age of 12 years and older living with moderate to severe plaque psoriasis, a chronic autoimmune disease that affects from 0.5 to 2% of the general population during childhood and adolescence. (2)

References:

  1. ClinicalTrials.gov. NCT01090427 Available at: www.clinicaltrials.gov/show/NCT01090427 (last accessed May 2015).
  2. Fotiadou C et al. Management of psoriasis in adolescence. Adolesc Health Med Ther 2014;5:25–34.


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn